Blood Cancer

Blood cancer, or hematological malignancy / haematolymphoid tumors, encompasses a cluster of devastating diseases that wreak havoc on the delicate balance of the blood, lymphatic system, and bone marrow. At Alfa Cytology, we have dedicated to unraveling the complexities of this disease, driven by a relentless pursuit of innovative solutions.

Introduction to Blood Cancer

It is projected that by 2040, over 1.85 million new blood cancer cases will be diagnosed globally. The report further estimates that by 2040, around 1,100,000 deaths will occur worldwide due to blood cancer. The increasing number of deaths and the surging incidence of blood cancer cases are propelling the growth of the blood cancer drug market. The primary categories of blood cancer drugs target leukemia and lymphoma.

Fig.1 Types of Blood Cancer. (Garg, A., et al., 2021)

Therapy Development for Blood Cancer

The blood cancer drugs market size has grown strongly in recent years. It will grow from $69.16 billion in 2023 to $74.77 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%.

Recent Developments

• May 2023: Bristol-Myers Squibb disclosed key results from phase 1/2 of the Breyanzi study. The drug is designed to treat patients with relapsed chronic lymphocytic leukemia (CLL).
• August 2023: Talvey, a groundbreaking drug for the treatment of multiple myeloma, received conditional approval. The drug is the second bispecific antibody developed by Johnson & Johnson. It is a first-of-its-kind drug because it binds to CD3 and GPRC5D, two proteins found in T cells and malignant plasma cells.

Our Services

This surge in market size underscores the increasing demand for effective and innovative therapy solutions. At Alfa Cytology, our state-of-the-art preclinical research facilities and specialized team of biologists and scientists are dedicated to conducting groundbreaking in vitro and in vivo studies to explore novel therapeutic approaches, validate potential biomarkers, and uncover the underlying mechanisms of these complex diseases.

Our preclinical services encompass a wide range of capabilities, including cell line development, high-throughput screening, pharmacokinetic and pharmacodynamic evaluations, and advanced animal models.

At Alfa Cytology, we offer a comprehensive suite of services tailored to the unique needs of our clients. Our team of seasoned experts has a deep understanding of the various subtypes of blood cancer, including leukemia, lymphoma, and myeloma, and the distinct genetic and molecular profiles that define them. For more information about our blood cancer research and development initiatives, or to inquire about our comprehensive services, please don't hesitate to contact us.

For research use only.